Winters Chad 4

What Happened Chad Winters, Vice President and Chief Accounting Officer of West Pharmaceutical Services (WST), had restricted stock units vest on Feb 20, 2026, converting into 89.328 common shares. To cover tax withholding, 30.184 of those shares were withheld/disposed at $241.12 per share for a reported amount of $7,278, resulting in a net delivery of 59.144 shares to Winters. This was a vesting of an award (RSUs), not an open-market purchase or voluntary sale.

Key Details

• Transaction date: February 20, 2026 (reported on Form 4 filed Feb 23, 2026). Filing appears timely.
• Vesting/conversion: 89.328 shares (transaction code M — exercise/conversion of derivative).
• Tax withholding/disposition: 30.184 shares withheld (transaction code F) at $241.12 per share; reported value $7,278.
• Net shares received: 59.144 shares (89.328 − 30.184).
• Shares owned after transaction: not stated in the filing.
• Footnotes: F1 notes RSUs convert 1:1 to common stock. F2 states the RSUs were a 356-share grant on Feb 18, 2025 vesting in four equal annual installments on Feb 20 each year.
• Transaction type interpretation: M = conversion of RSU award; F = share withholding to satisfy tax obligation.

Context This was a routine RSU vesting and a tax-withholding disposition — a common administrative step when equity awards vest. The small cash value reported (~$7.3k) reflects the shares withheld for taxes, not an open-market sale expressing sentiment.